Le Lézard
Classified in: Health
Subject: SVY

Medical Cannabis and Reduced Prescription Use


ALBUQUERQUE, N.M., Aug. 18, 2017 /PRNewswire/ -- In a soon-to-be published article in the *Journal of the American Medical Directors Association, *University of New Mexico researchers, in
collaboration with Industrial Rehabilitation Clinics of Albuquerque, followed patients who enrolled voluntarily in the New Mexico state medical cannabis program and found that they significantly reduced their utilization of scheduled prescription medications in the months following enrollment. All prescriptions for scheduled medications must be reported to the New Mexico Prescription Monitoring Program with opiates and benzodiazepines being the two most common. Based on these prescription records, patients enrolled in the medical cannabis program reduced the monthly average number of prescriptions, types of prescriptions (drug classes), number of prescribers, and number of related pharmacy visits. 71% of medical cannabis program enrollees either ceased or reduced their use of scheduled prescriptions within 6 months of enrolling.

While other studies on medical cannabis have looked at similar state-level outcomes, this study is the first to take the approach of examining individual patients throughout their enrollment in the medical cannabis program and comparing those patients to a comparison group of similar patients who did not enroll in the medical cannabis program. 

The findings of this study indicate that once a patient enrolls in the medical cannabis program there is an increased likelihood that the patient will decrease their usage of scheduled medications. These medications include many drugs of abuse such as opiates, benzodiazepines, and sleeping medications. Opiates in particular are in the public discourse because of the danger of overdose, addiction and death. 

Stith, S. S., et al "Effects of Legal Access to Cannabis on Scheduled II-V Drug Prescriptions." (in press). Journal of the American Medical Director's Association.

Press Contact 
Anthony Reeve, M.D.

Phone: (505) 515-8033
Email: [email protected] 

Related Images

image1.jpg

image2.jpg

 

SOURCE Industrial Rehabilitation Clinics of Albuquerque


These press releases may also interest you

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...



News published on and distributed by: